Urol. praxi. 2018;19(3):121-125 | DOI: 10.36290/uro.2018.069

Combined bladder-saving procedures in the treatment of locally advanced urothelial tumors

MUDr. Tomáš Svoboda, Ph.D.
Onkologická a radioterapeutická klinika FN Plzeň

Radical cystectomy with pelvic lymphadenectomy is the basic curative treatment for patients with advanced urothelial urinarybladder carcinoma. However, surgical treatment is quite often unfeasible from technical or other reasons or there is a patientwish to maintain his quality of life by urinary bladder sparing. Oncological treatment in the form of platinum-based neoadjuvantchemotherapy is associated with a high number of treatment responses, complete remision incl. and with an overall survivalimprovement, moreover, there is higher probability of bladder sparing surgery.

Keywords: neoadjuvant chemotherapy, cisplatin, gencitabine, urothelial urinary bladder carcinoma, radical cystectomy, immunotherapy

Published: July 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svoboda T. Combined bladder-saving procedures in the treatment of locally advanced urothelial tumors. Urol. praxi. 2018;19(3):121-125. doi: 10.36290/uro.2018.069.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. ÚZIS ČR, www.svod.cz. Novotvary 2015, Národní onkologický registr, ÚZIS, Praha 2017.
    2. Modrá kniha ČOS, 23. aktualizace. Brno 3/2017.
    3. Witjes JA, Comperat E, Cowan NC, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2013 guidelines. Eur Urol 2014; 65: 778-792. Go to original source... Go to PubMed...
    4. Petrelli F, Coinu A, Cabiddu M, et al. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: A meta-analysis. Eur Urol 2014; 65: 350-357. Go to original source... Go to PubMed...
    5. Rosenblatt R, Sherif A, Rintala E, et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscleinvasive urothelial bladder cancer. Eur Urol 2012; 61: 1229-1238. Go to original source... Go to PubMed...
    6. Sherif A, Holmberg L, Rintala E, et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: A combined analysis of two Nordic studies. Eur Urol 2004; 45: 297-303. Go to original source... Go to PubMed...
    7. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859-866. Go to original source... Go to PubMed...
    8. Kitamura H, Tsukamoto T, Shibata T, et al. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209. Ann Oncol 2014; 25: 1192-1198. Go to original source... Go to PubMed...
    9. International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscleinvasive bladder cancer: Long-term results of the BA06 30894 trial. J Clin Oncol 2011; 29: 2171-2177. Go to original source... Go to PubMed...
    10. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: Update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005; 48: 202-205. Go to original source... Go to PubMed...
    11. Yin M, Joshi M, Meuer RP, et al. Neoadjuvant chemotherapy for Muscle-Invasive Bladder Cancer: A Systemic review and two-step meta-analysis. The Oncologist 2016; 21: 1-7. Go to original source... Go to PubMed...
    12. Zargar H, Espiritu PN, Fairey AS, et al. Multicenter assessment of neoadjuvant chemotherapy for muscle invasive bladder cancer. Eur Urol 2015; 67: 241-249. Go to original source... Go to PubMed...
    13. Plimack ER, Hoffman-Censitz JH, Viterbo R, et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J Clin Oncol 2014; 32: 1895-1901. Go to original source... Go to PubMed...
    14. Krause F, Ott O, Haeberle B, et al. Validation of a trimodalitiy treatment and selective organ preservation for bladder cancer: Influence of clinical different parameters on the 15-year long-term outcome. J Clin Oncol 2010; 28: 15s: suppl; abstr 4575. Go to original source...
    15. McConkey DJ, Choi W, Shen Y, et al. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-na?ve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol 2016; 69: 855-862. Go to original source... Go to PubMed...
    16. Matoušková M, Svoboda T. Multimodální přístup k nádorům močového měchýře a prostaty. Olomouc: Solen 2018: 309 s.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.